Chromophobe renal cell carcinoma with metastatic progression and cabozantinib-induced hand-foot syndrome

dc.contributor.authorEsmez, Omer
dc.contributor.authorEsmez, Merve Yildiz
dc.contributor.authorDeniz, Gulnihal
dc.date.accessioned2026-08-12T17:11:18Z
dc.date.issued2025
dc.departmentFırat Üniversitesi
dc.description.abstractRenal cell carcinoma (RCC) comprises a heterogeneous group of neoplasms with variable prognoses. Chromophobe RCC, a relatively uncommon subtype, generally follows an indolent clinical course but may occasionally exhibit aggressive or metastatic behaviour. This report describes a woman in the mid 60s with a history of partial nephrectomy for chromophobe RCC who subsequently developed metastatic disease. Systemic treatment with cabozantinib was initiated, resulting in dermatological toxicity. Serial imaging over 4 years demonstrated progressive metastatic involvement, including hepatic lesions. This account underscores the challenges of managing metastatic chromophobe RCC, differentiating true recurrence from potential second primary malignancies and addressing the adverse effects of targeted therapies such as cabozantinib.
dc.identifier.doi10.1136/bcr-2025-266596
dc.identifier.issn1757-790X
dc.identifier.issue11
dc.identifier.orcid0000-0002-4475-3501
dc.identifier.pmid41198159
dc.identifier.scopus2-s2.0-105021068427
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1136/bcr-2025-266596
dc.identifier.urihttps://hdl.handle.net/11508/51104
dc.identifier.volume18
dc.identifier.wosWOS:001609409700001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmj Publishing Group
dc.relation.ispartofBmj Case Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectRenal system
dc.subjectSkin
dc.subjectUrological cancer
dc.titleChromophobe renal cell carcinoma with metastatic progression and cabozantinib-induced hand-foot syndrome
dc.typeArticle

Dosyalar